Literature DB >> 2692700

Ocular myasthenia gravis after D-penicillamine administration.

L J Katz1, R L Lesser, J R Merikangas, J P Silverman.   

Abstract

A 68-year-old black woman who was put on D-penicillamine therapy (250-500 mg per day, total dose 15 g) for rheumatoid arthritis developed ocular myasthenia gravis. Two weeks after she discontinued D-penicillamine her signs and symptoms cleared with no other treatment. Review of previous cases and possible immunological mechanisms are discussed.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2692700      PMCID： PMC1041959          DOI： 10.1136/bjo.73.12.1015

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


  25 in total

1.  Effect of penicillamine on the proliferative response of human lymphocytes.

Authors:  P Merryman; I A Jaffee
Journal:  Proc Soc Exp Biol Med       Date:  1978-01

2.  [Pemphigus induced by D-penicillamine in rheumatoid arthritis. Study of 5 cases and systematic study of anti-intercellular substance antibodies of the skin in the course of treatment].

Authors:  M Benveniste; J Crouzet; J C Homberg; M Lessana; J P Camus; J Hewitt
Journal:  Nouv Presse Med       Date:  1975-12-20

3.  Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies.

Authors:  C L Masters; R L Dawkins; P J Zilko; J A Simpson; R J Leedman
Journal:  Am J Med       Date:  1977-11       Impact factor: 4.965

4.  HLA antigens in pencillamine-induced myasthenia gravis.

Authors:  J Keesey; S Novom
Journal:  Neurology       Date:  1979-04       Impact factor: 9.910

5.  D-penicillamine induced Goodpasture's syndrome in Wilson's disease.

Authors:  I Sternlieb; B Bennett; I H Scheinberg
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

6.  Ptosis and weakness after start of D-penicillamine therapy.

Authors:  S G Atcheson; J R Ward
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

7.  Mechanism of the antidepressant action of electroconvulsive therapy.

Authors:  D G Grahame-Smith; A R Green; D W Costain
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

8.  Penicillamine-induced myasthenia gravis.

Authors:  W R Sundstrom; A A Schuna
Journal:  Arthritis Rheum       Date:  1979-02

9.  Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis.

Authors:  O Epstein; D De Villiers; S Jain; B J Potter; H C Thomas; S Sherlock
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

10.  Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor.

Authors:  A S Russell; J M Lindstrom
Journal:  Neurology       Date:  1978-08       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.